NCT06451497View on ClinicalTrials.gov

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Non Small Cell Lung CancerEsophageal CancerHead and Neck Squamous Cell CarcinomaPancreas AdenocarcinomaBiliary Tract CancerProstate CancerUrothelial CarcinomaColorectal CancerTriple Negative Breast CancerHigh Grade Ovarian Serous AdenocarcinomaDiffuse Large B Cell Lymphoma
Interventions
BIOLOGICAL

ZM008

Intravenous delivery

Trial Locations (3)

78229

RECRUITING

NEXT Oncology, San Antonio

78758

RECRUITING

NEXT Oncology, Austin

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Zumutor Biologics Inc.

INDUSTRY